Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: PRME primemedicine.com
Prime Medicine is a biotechnology company developing a new class of one-time curative genetic therapies using its proprietary Prime Editing platform. Prime Editing is a versatile, precise, and efficient gene editing technology designed to make targeted corrections at specific positions within a gene while minimizing unwanted DNA modifications. The company's diversified pipeline is organized around three core therapeutic areas: liver, lung, and immunology/oncology. Key programs include PM577a for Wilson disease (in vivo liver-targeted, now in a global Phase 1/2 program), PM647 for Alpha-1 Antitrypsin Deficiency (in vivo liver-targeted, approaching regulatory submission), PM359 for chronic granulomatous disease (ex vivo, with RMAT designation and BLA submission planned), an in vivo cystic fibrosis program supported by the Cystic Fibrosis Foundation, and Prime Edited CAR-T products for hematology, immunology, and oncology in partnership with Bristol Myers Squibb. The company trades on Nasdaq under the ticker PRME and is pre-commercial, generating limited collaboration revenue while investing heavily in R&D to advance its clinical pipeline. Updated
Berkshire Hathaway has resumed acquiring shares of Warren Buffett's favorite media stock. Other insider buyers are focused on three biotech stocks.
You’ve likely heard that penny stocks are high-risk investments, and if so, you’ve heard right. However, a significant part of investing is finding the right balance between risk and reward. As you…
Public offerings of stock tempted some insider buying, and one insider stepped up to support a struggling online delivery service provider.
Prime Medicine is a biotechnology company developing a new class of one-time curative genetic therapies using its proprietary Prime Editing platform.
The Wall Street consensus 12-month price target for PRME is $7.11.
